PURE Bioscience (OTCMKTS:PURE) CEO Henry R. Lambert sold 41,500 shares of PURE Bioscience stock in a transaction on Friday, January 12th. The stock was sold at an average price of $0.93, for a total transaction of $38,595.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
PURE Bioscience (OTCMKTS PURE) traded down $0.05 during mid-day trading on Monday, hitting $0.88. 5,675 shares of the company were exchanged, compared to its average volume of 34,316. PURE Bioscience has a 52-week low of $0.83 and a 52-week high of $1.36. The stock has a market cap of $59.78, a PE ratio of -8.00 and a beta of -1.80.
PURE Bioscience (OTCMKTS:PURE) last released its quarterly earnings results on Thursday, December 14th. The company reported ($0.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.02). PURE Bioscience had a negative return on equity of 210.88% and a negative net margin of 388.83%. The firm had revenue of $0.46 million for the quarter, compared to analysts’ expectations of $0.65 million. analysts anticipate that PURE Bioscience will post -0.08 EPS for the current year.
Separately, ValuEngine raised shares of PURE Bioscience from a “sell” rating to a “hold” rating in a research note on Wednesday, November 29th.
ILLEGAL ACTIVITY NOTICE: “Insider Selling: PURE Bioscience (OTCMKTS:PURE) CEO Sells 41,500 Shares of Stock” was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://ledgergazette.com/2018/02/06/henry-r-lambert-sells-41500-shares-of-pure-bioscience-pure-stock.html.
About PURE Bioscience
PURE Bioscience, Inc is focused on developing and commercializing antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control. The Company’s technology platform is based on stabilized ionic silver and its products contain silver dihydrogen citrate (SDC).
Receive News & Ratings for PURE Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PURE Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.